Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence

Prader–Willi syndrome (PWS) combines genetically determined hyperphagia, altered body composition, growth hormone (GH) axis abnormalities, and progressive obesity, creating a metabolic context that differs from non-syndromic obesity (NSO). Whether PWS confers a uniformly more atherogenic lipid phenotype remains uncertain. This critical narrative review synthesizes pediatric evidence on conventional lipids, lipidomic remodeling, and their relationships with adiposity, insulin sensitivity, inflammation, body composition, genotype, and recombinant human GH (rhGH) exposure. More adverse conventional lipid profiles have been reported mainly in cohorts without rigorous matching for adiposity or body composition; these findings cannot be assumed to represent an independent syndrome effect. In contrast, a GH-naive cohort with similar BMI to NSO controls showed markedly higher lipoprotein(a) in PWS but broadly similar triglyceride, HDL-C, and LDL-C concentrations. Lipidomic evidence is more limited: a single pediatric discovery cohort reported lower total phosphatidylcholine and lysophosphatidylcholine concentrations in PWS than in NSO and normal-weight controls, together with exploratory PWS-specific associations between selected phospholipid species, BMI, and gut microbial taxa. These molecular findings have not yet been independently replicated and should not be interpreted as a validated diagnostic or prognostic signature. Overall, conventional lipid assessment remains the clinical standard and should be interpreted alongside adiposity, lean mass, pubertal stage, and rhGH exposure. Lipidomics currently provides mechanistic and hypothesis-generating information rather than a PWS-specific clinical risk-stratification tool.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-11-20
DOI
https://doi.org/10.3389/fendo.2026.2000348
Primary Topic
Genetic Syndromes and Imprinting
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence

张会丰, Kaixi Wang, Yutong Xing, Xinyu Ma et al.
2 links
Frontiers in Endocrinology
Genetic Syndromes and Imprinting
article

Lipid metabolic phenotypes in pediatric Prader–Willi syndrome versus non-syndromic obesity: conventional lipids and emerging lipidomic evidence

张会丰, Kaixi Wang, Yutong Xing, Xinyu Ma, Yalei Pi, Yanan Zhang
article en

Abstract

Prader–Willi syndrome (PWS) combines genetically determined hyperphagia, altered body composition, growth hormone (GH) axis abnormalities, and progressive obesity, creating a metabolic context that differs from non-syndromic obesity (NSO). Whether PWS confers a uniformly more atherogenic lipid phenotype remains uncertain. This critical narrative review synthesizes pediatric evidence on conventional lipids, lipidomic remodeling, and their relationships with adiposity, insulin sensitivity, inflammation, body composition, genotype, and recombinant human GH (rhGH) exposure. More adverse conventional lipid profiles have been reported mainly in cohorts without rigorous matching for adiposity or body composition; these findings cannot be assumed to represent an independent syndrome effect. In contrast, a GH-naive cohort with similar BMI to NSO controls showed markedly higher lipoprotein(a) in PWS but broadly similar triglyceride, HDL-C, and LDL-C concentrations. Lipidomic evidence is more limited: a single pediatric discovery cohort reported lower total phosphatidylcholine and lysophosphatidylcholine concentrations in PWS than in NSO and normal-weight controls, together with exploratory PWS-specific associations between selected phospholipid species, BMI, and gut microbial taxa. These molecular findings have not yet been independently replicated and should not be interpreted as a validated diagnostic or prognostic signature. Overall, conventional lipid assessment remains the clinical standard and should be interpreted alongside adiposity, lean mass, pubertal stage, and rhGH exposure. Lipidomics currently provides mechanistic and hypothesis-generating information rather than a PWS-specific clinical risk-stratification tool.

Frontiers in EndocrinologyVol. 17
Second Hospital of Hebei Medical University (CN)
Good health and well-being
Genetic Syndromes and Imprinting
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon